Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Antioxidant MitoQ tested for boosting cold tolerance in black individuals

NCT ID NCT06784531

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a supplement called MitoQ can improve skin blood flow and temperature in the cold, and if it helps Black individuals more, since they face higher cold injury risk. 26 healthy adults took part. The goal was to understand if antioxidants can reduce blood vessel narrowing caused by cold exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

Sep 2024

Finished

Oct 2025

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, age 18-40 * In good health as determined by OMSO (Office of Medical Support and Oversight) * Willing to refrain from exercise and caffeinated or alcoholic beverages for 12 hours before each testing session * Willing to refrain from antioxidant-rich foods, such as blueberries, pecans, and dark chocolate, 48 h before each testing session * Eumenorrheic females (menstrual cycle length between 24-35 days) or females taking oral contraceptives, or utilizing implantable contraception (e.g., intrauterine device) * Have supervisor approval if active-duty military or a federal employee at NSSC Exclusion Criteria: * History of cold injuries of any severity (e.g., frostbite, trench foot, chilblains) * Raynaud's syndrome * Cold-induced asthma/bronchospasm * Previous hand/finger injuries that impair dexterity and hand function * Metal hardware (plates/screws) in the forearms and hands * Smoke, vape, or use smokeless tobacco or other nicotine-containing products habitually (unless have quit \> 4 months prior) * Current use of medications (except for birth control) or dietary supplements that could alter cardiovascular, thermoregulatory, or vascular control (e.g., anti-hypertensives, statins) * History of disease of the gastrointestinal tract including (but not limited to) diverticulosis, diverticulitis and inflammatory bowel disease, peptic ulcer disease, Crohn's disease, ulcerative colitis; or previous gastrointestinal surgery * Have a history of renal disease including (but not limited to) chronic kidney disease, acute kidney injury, kidney stone disease, glomerular disease, or nephritis * Known allergies to medical adhesives * Known allergy to MitoQ * Difficulty swallowing pills * Heart, lung, kidney, muscle, or nerve disorder(s) * A planned MRI during the study or within 3 days after completing a cold test * Women who are pregnant, planning to become pregnant, or breastfeeding * Not willing to have small areas of skin on the body shaved (if deemed necessary for attachment of study instrumentation) * Have donated blood within 8 weeks of the study or plan to donate blood during the study * Lesions on a significant portion of the upper extremities due to skin pigmentation disorders (e.g., vitiligo, psoriasis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cold exposure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • U.S. Army Research Institute of Environmental Medicine

    Natick, Massachusetts, 01760, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.